76 related articles for article (PubMed ID: 22031621)
1. Food increased the bioavailability of BMS-690514, an orally active EGFR/HER2/VEGF receptor kinase inhibitor, in healthy subjects.
Vakkalagadda B; Park JS; Ahlers CM; Dorizio S; Has T; Roongta V; Heller KN; Derbin GM; Zhang S
J Clin Pharmacol; 2012 Sep; 52(9):1350-6. PubMed ID: 22031621
[TBL] [Abstract][Full Text] [Related]
2. Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
Soria JC; Baselga J; Hanna N; Laurie SA; Bahleda R; Felip E; Calvo E; Armand JP; Shepherd FA; Harbison CT; Berman D; Park JS; Zhang S; Vakkalagadda B; Kurland JF; Pathak AK; Herbst RS
Eur J Cancer; 2013 May; 49(8):1815-24. PubMed ID: 23490650
[TBL] [Abstract][Full Text] [Related]
3. Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.
Christopher LJ; Hong H; Vakkalagadda BJ; Clemens PL; Su H; Roongta V; Allentoff A; Sun H; Heller K; Harbison CT; Iyer RA; Humphreys WG; Wong T; Zhang S
Drug Metab Dispos; 2010 Nov; 38(11):2049-59. PubMed ID: 20668249
[TBL] [Abstract][Full Text] [Related]
4. Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers.
Derks M; Kawamura H; Abt M; Meneses-Lorente G; Phelan M; Ishikawa T
Clin Ther; 2011 Jun; 33(6):754-65. PubMed ID: 21704240
[TBL] [Abstract][Full Text] [Related]
5. Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adults.
Musson DG; Kramer WG; Foehr ED; Bieberdorf FA; Hornfeldt CS; Kim SS; Dorenbaum A
Clin Ther; 2010 Feb; 32(2):338-46. PubMed ID: 20206791
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants: assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulations.
Yang Z; Vakkalagadda B; Shen G; Ahlers CM; Has T; Christopher LJ; Kurland JF; Roongta V; Masson E; Zhang S
J Clin Pharmacol; 2013 Feb; 53(2):217-27. PubMed ID: 23436267
[TBL] [Abstract][Full Text] [Related]
7. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
[TBL] [Abstract][Full Text] [Related]
8. Metabolism and disposition of [14C]BMS-690514 after oral administration to rats, rabbits, and dogs.
Hong H; Su H; Sun H; Allentoff A; Ekhato IV; Chando T; Caceres-Cortes J; Roongta V; Iyer RA; Humphreys WG; Christopher LJ
Drug Metab Dispos; 2010 Jul; 38(7):1189-201. PubMed ID: 20363952
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers.
Pithavala YK; Chen Y; Toh M; Selaru P; LaBadie RR; Garrett M; Hee B; Mount J; Ni G; Klamerus KJ; Tortorici MA
Cancer Chemother Pharmacol; 2012 Jul; 70(1):103-12. PubMed ID: 22644797
[TBL] [Abstract][Full Text] [Related]
10. Bioequivalence study of two different tablet formulations of donepezil using truncated areas under the curve. A single-center, single-dose, randomized, open-label, 2-way crossover study under fasting conditions.
Almeida S; Filipe A; Neves R; Desjardins I; Shink E; Castillo A
Arzneimittelforschung; 2010; 60(3):116-23. PubMed ID: 20422942
[TBL] [Abstract][Full Text] [Related]
11. The effect of food on the absorption of oral ziprasidone.
Miceli JJ; Glue P; Alderman J; Wilner K
Psychopharmacol Bull; 2007; 40(3):58-68. PubMed ID: 18007569
[TBL] [Abstract][Full Text] [Related]
12. Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
Godfrey AR; Digiacinto J; Davis MW
Clin Ther; 2011 Jun; 33(6):766-75. PubMed ID: 21704241
[TBL] [Abstract][Full Text] [Related]
13. Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects.
Henney HR; Shah J
Clin Ther; 2007 Apr; 29(4):661-9. PubMed ID: 17617289
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the effects of a high-fat meal on the oral bioavailability of a single dose of preladenant in healthy subjects.
Cutler DL; Tendolkar A; Grachev ID
J Clin Pharmacol; 2012 Nov; 52(11):1698-703. PubMed ID: 22167566
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, and pharmacokinetics of TAS-108 in normal healthy post-menopausal female subjects: a phase I study on single oral dose.
Yamaya H; Yoshida K; Kuritani J; Yonezawa J; Tsuda M; Shindo T; Nagayama S; Buzdar AU
J Clin Pharm Ther; 2005 Oct; 30(5):459-70. PubMed ID: 16164493
[TBL] [Abstract][Full Text] [Related]
16. Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads.
Damle BD; Yan JH; Behr D; O'Mara E; Nichola P; Kaul S; Knupp C
J Clin Pharmacol; 2002 Apr; 42(4):419-27. PubMed ID: 11936567
[TBL] [Abstract][Full Text] [Related]
17. Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers.
Teng R; Mitchell PD; Butler K
J Clin Pharm Ther; 2012 Aug; 37(4):464-8. PubMed ID: 21967645
[TBL] [Abstract][Full Text] [Related]
18. Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals.
Ling J; Fettner S; Lum BL; Riek M; Rakhit A
Anticancer Drugs; 2008 Feb; 19(2):209-16. PubMed ID: 18176118
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors.
Heath EI; Chiorean EG; Sweeney CJ; Hodge JP; Lager JJ; Forman K; Malburg L; Arumugham T; Dar MM; Suttle AB; Gainer SD; LoRusso P
Clin Pharmacol Ther; 2010 Dec; 88(6):818-23. PubMed ID: 20980999
[TBL] [Abstract][Full Text] [Related]
20. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
Penn R; Williams RX; Guha-Ray DK; Sawyers WG; Braun SL; Rains KT
Clin Ther; 2006 Jan; 28(1):45-54. PubMed ID: 16490579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
